RT: Maria, Head of Emerging Infectious Diseases and Zoonotic Infectious Diseases of the World Health Organization (WHO), at a press conference on the status of the coronavirus at the United Nations in Geneva, Switzerland, on January 29, 2020. Van Kerkhove will give a talk.
Dennis Bali Bose | Reuters
Merck’World Health Organization officials said Tuesday that the experimental antiviral drug would be effective against the most serious consequences of Covid-19, as international organizations are waiting for clinical trial data for the drug. Good news. “
“We look forward to receiving data from them,” said Maria Van Kerkhove, WHO’s Covid technical lead, in a virtual Q & A. “We think everyone wants early treatment to prevent people from actually getting into that serious condition and actually dying from illness.”
U.S. pharmaceutical company Friday said The drug, known as molnupiravir, has been shown in a phase 3 study to reduce the risk of hospitalization or death in adults with mild to moderate Covid cases by approximately 50%. It works by blocking the replication of the virus in the body.
Unlike the intravenous drug remdesivir from Gilead Sciences, Merck’s molnupiravir can be taken orally. If approved by the Food and Drug Administration, it will be the first pill to treat Covid. This is a potentially game-changing advance in the fight against viruses, killing an average of more than 1,700 Americans per day.
Vaccination is still the best preventive measure against the virus, but health experts want tablets like Merck to prevent the progression of the disease and prevent travel to hospitals in infected people.
Tablets like Merck are considered a kind of “holy grail” for treatment, said Dr. Mike Ryan, Secretary-General of the WHO Emergency Program. He said authorities were still waiting to see raw clinical trial data on the drug.
“If you can stop the virus before someone gets very ill, it’s a game changer in that sense,” he said.
Other pharmaceutical companies are also working on antiviral drugs. Tablets developed by PfizerWill use BioNTech to develop the first licensed Covid vaccine in the United States, which could be available by the end of this year, CEO Albert Bourla told CNBC in April.
Ryan also said world leaders and public health officials need to think about how much the drug could cost patients. According to the New York Times, a five-day course of the drug costs the federal government about $ 700 per patient. This is one-third of the current cost of monoclonal antibodies.
“The cost of treating millions of people early can be quite expensive and probably worth the investment, but we need to consider how it works.” Said Ryan.
WHO says antivirals are good news as they are waiting for data
Source link WHO says antivirals are good news as they are waiting for data
The post WHO says antivirals are good news as they are waiting for data appeared first on Eminetra.